NEW YORK – Fluidigm on Thursday said it has entered into a pair of comarketing agreements related to its Imaging Mass Cytometry technology platform.
Under a comarketing agreement with Ultivue, the companies will collaborate to offer a comprehensive portfolio of solutions for biomarker discovery and drug development. Cambridge, Massachusetts-based Ultivue uses its InSituPlex technology to develop assays for use in multiplex immunofluorescence imaging and analysis.
Fluidigm's IMC technology, meanwhile, is designed for highly multiplexed, targeted interrogation of tissue sections for 40 or more protein markers per scan. Combining the two platforms provides researchers with an end-to-end service for clinical and translational research, the companies said.
Fluidigm also inked a collaboration and comarketing agreement with ImaBiotech, a contract research organization that offers spatial multiomics services to pharmaceutical researchers with an emphasis on precision medicine approaches to evaluating drug efficacy and toxicity.
ImaBiotech will use Fluidigm's Hyperion Imaging System to offer mass cytometry as one of its core technologies out of its GLP research facilities in the US and Europe.
"Our customers expressed a need for high-multiplex imaging, and that compelled us to acquire a Hyperion Imaging System to meet market needs," ImaBiotech CEO Jonathan Stauber said in a statement. "We are excited for the opportunity to collaborate with Fluidigm in this regard, innovating applications and products, including new panel development, to make Imaging Mass Cytometry an even more powerful tool."